SCHEMBL21569705

SCHEMBL21569705

O=S(=O)(NCCc1ccccc1C(F)(F)F)c1c(Cl)cccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.48
CNR1 P21554 1/20 0.46
SLC22A12 Q96S37 1/20 0.43
MCL1 Q07820 1/20 0.42
PTGS2 P35354 1/20 0.41
DPP4 P27487 1/20 0.40
DPP8 Q6V1X1 1/20 0.40
POLB P06746 1/20 0.40
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
CCR1 P32246 1/20 0.38
AKR1C3 P42330 1/20 0.38
HSD17B13 Q7Z5P4 1/20 0.37
NPY1R P25929 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21569862 0.91 CNR1 (0.42) L3MBTL1CNR1SLC22A12PTGS2DPP4
SCHEMBL21569699 0.87 CNR1 (0.43) L3MBTL1CNR1SLC22A12DPP4DPP8
SCHEMBL21569706 0.84 L3MBTL1 (0.56) L3MBTL1CNR1POLBKDM4EALDH1A1
SCHEMBL21569701 0.82 AKR1C3 (0.54) L3MBTL1CNR1KDM4EALDH1A1TDP1
SCHEMBL21569696 0.80 MCL1 (0.44) L3MBTL1MCL1
SCHEMBL21569863 0.79 MEN1 (0.62) L3MBTL1POLBCYP1A2CYP3A4MAPK1
SCHEMBL21569714 0.79 L3MBTL1 (0.51) L3MBTL1KDM4EALDH1A1TDP1CYP1A2
SCHEMBL31500481 0.79 L3MBTL1 (0.51) L3MBTL1KDM4EALDH1A1TDP1CYP1A2
SCHEMBL13158488 0.77 NQO2 (0.56) CNR1SLC22A12POLBKDM4EALDH1A1
SCHEMBL21569864 0.75 L3MBTL1 (0.47) L3MBTL1KDM4EALDH1A1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136545-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2025-05-01 US claimed
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2021-06-10 US claimed
US-20250136545-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2025-05-01 US disclosed
US-12202790-B2 Sulfonamide derivatives having selective Nox inhibiting activity GLUCOX BIOTECH AB (SE) 2025-01-21 US disclosed
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2021-06-10 US disclosed
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2021-06-10 US disclosed
WO-2019215291-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12202790-B2 Sulfonamide derivatives having selective Nox inhibiting activity NOX4, NOX1, NOX5 L3MBTL1 4858/4885CNR1 2219/4885SLC22A12 1667/4885
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY NOX4, NOX1, NOX5 L3MBTL1 4838/4885CNR1 2213/4885SLC22A12 1058/4885
US-20250136545-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY NOX4, NOX1, NOX5 L3MBTL1 4838/4885CNR1 2213/4885SLC22A12 1058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.